Search

Search Constraints

You searched for: Author/Creator Petersson, Joel

Search Results

1. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. (9th February 2019)

2. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. (25th April 2018)

7. A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)

8. PYRAMID Registry: Long‐term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohn's Disease: 694. (October 2017)

9. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. Issue 9 (8th February 2019)

10. S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study. (October 2020)